These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1851 related items for PubMed ID: 20216409

  • 1. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U, Kaldonska M, Klodowska-Duda G, Wyska E, Safranow K, Bialecka M, Gawronska-Szklarz B.
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [Abstract] [Full Text] [Related]

  • 2. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
    Ries V, Selzer R, Eichhorn T, Oertel WH, Eggert K, German Tolcapone Study Group.
    Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.
    Napolitano A, Del Dotto P, Petrozzi L, Dell'Agnello G, Bellini G, Gambaccini G, Bonuccelli U.
    Clin Neuropharmacol; 1999 May; 22(1):24-9. PubMed ID: 10047930
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.
    Baas H, Zehrden F, Selzer R, Kohnen R, Loetsch J, Harder S.
    Clin Pharmacokinet; 2001 May; 40(5):383-93. PubMed ID: 11432539
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T, Machado R, Rocha JF, Fernandes-Lopes C, Costa R, Torrão L, Loureiro AI, Falcão A, Vaz-da-Silva M, Wright L, Almeida L, Soares-da-Silva P.
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [Abstract] [Full Text] [Related]

  • 6. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [Abstract] [Full Text] [Related]

  • 7. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
    Ishihara A, Miyachi T, Nakamura T, Ohtsuki T, Kimura Y, Kihira K, Yamawaki T, Matsumoto M.
    Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
    [Abstract] [Full Text] [Related]

  • 8. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW.
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [Abstract] [Full Text] [Related]

  • 9. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M, Yokochi M, Kuno S, Hattori Y, Tsukamoto Y, Narabayashi H, Tohgi H, Mizuno Y, Kowa H, Yanagisawa N, Kanazawa I.
    J Neural Transm (Vienna); 1997 Jul; 104(2-3):229-36. PubMed ID: 9203084
    [Abstract] [Full Text] [Related]

  • 10. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
    Jorga K, Banken L, Fotteler B, Snell P, Steimer JL.
    Clin Pharmacol Ther; 2000 Jun; 67(6):610-20. PubMed ID: 10872643
    [Abstract] [Full Text] [Related]

  • 11. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
    Blandini F, Nappi G, Fancellu R, Mangiagalli A, Samuele A, Riboldazzi G, Calandrella D, Pacchetti C, Bono G, Martignoni E.
    J Neural Transm (Vienna); 2003 Aug; 110(8):911-22. PubMed ID: 12898346
    [Abstract] [Full Text] [Related]

  • 12. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F, Lilliu H, Le Pen C.
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [Abstract] [Full Text] [Related]

  • 13. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM, Sedek G, Fotteler B, Zürcher G, Nielsen T, Aitken JW.
    Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
    [Abstract] [Full Text] [Related]

  • 14. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 15. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
    Rosqvist K, Horne M, Hagell P, Iwarsson S, Nilsson MH, Odin P.
    J Parkinsons Dis; 2018 Nov; 8(1):59-70. PubMed ID: 29480220
    [Abstract] [Full Text] [Related]

  • 16. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F, Marconi S.
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [Abstract] [Full Text] [Related]

  • 17. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
    Davis TL, Roznoski M, Burns RS.
    Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
    [Abstract] [Full Text] [Related]

  • 18. Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease.
    Harder S, Baas H.
    Clin Pharmacol Ther; 1998 Aug; 64(2):183-91. PubMed ID: 9728899
    [Abstract] [Full Text] [Related]

  • 19. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G.
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [Abstract] [Full Text] [Related]

  • 20. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
    Antonini A, Bondiolotti G, Natuzzi F, Bareggi SR.
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 93.